e-learning
resources
Munich 2014
Tuesday, 09.09.2014
ILDs 4
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Sulforaphane attenuates lung fibrosis in bleomycin-induced pulmonary fibrosis via inhibition of TGF-beta/Smad signaling
S. Y. Kyung, Y. J. Kim, S. M. Lee, S. M. Kang, S. P. Lee, J. W. Park, S. H. Jeong (Incheon, Republic Of Korea)
Source:
International Congress 2014 – ILDs 4
Session:
ILDs 4
Session type:
Thematic Poster Session
Number:
3754
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Y. Kyung, Y. J. Kim, S. M. Lee, S. M. Kang, S. P. Lee, J. W. Park, S. H. Jeong (Incheon, Republic Of Korea). Sulforaphane attenuates lung fibrosis in bleomycin-induced pulmonary fibrosis via inhibition of TGF-beta/Smad signaling. Eur Respir J 2014; 44: Suppl. 58, 3754
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Dasatinib suppresses TGFbeta-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis
Source: International Congress 2014 – ILDs 1
Year: 2014
Dissecting the role of TRPC6-channels in bleomycin-induced pulmonary fibrosis
Source: International Congress 2014 – ILDs 3
Year: 2014
Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 2
Year: 2014
Interdependence of HIF1alpha /TGFbeta1 activity in induction of pulmonary fibrosis
Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Year: 2013
Pirfenidone and BIBF1120 regulate properties of myofibroblasts
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Nintedanib (BIBF 1120) prevents TGF-beta-induced pro-fibrotic effects in primary human lung myofibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 1
Year: 2014
LATE-BREAKING ABSTRACT: The effects and mechanism of adiponectin on inhibiting pulmonary fibrosis
Source: International Congress 2014 – ILDs 1
Year: 2014
17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice
Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Year: 2013
Selective endothelin-A receptor blockade attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone
Source: International Congress 2014 – ILDs 1
Year: 2014
Pirfenidone attenuates myofibroblast differentiation during insufficient mitophagy
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 4
Year: 2014
Novel biomarkers in bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
Loss of PTEN induced lung fibroblasts exhibiting similar pathogenic features to cancer cells in idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 2
Year: 2014
Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 3
Year: 2014
Idiopathic pulmonary fibrosis is associated with a preferential alteration of kCO rather than of DLCO
Source: International Congress 2014 – ILDs 6
Year: 2014
Regulation of WISP1 by profibrotic cytokines in pulmonary fibrosis
Source: International Congress 2014 – Pulmonary fibrosis: receptors, signalling pathways and mesenchymal cells
Year: 2014
Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients
Source: International Congress 2015 – Pulmonary hypertension: promising small molecules
Year: 2015
Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta-mediated extracellular matrix protein production
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept